Added to YB: 2026-04-02
Pitch date: 2026-03-30
BNTX [neutral]
BioNTech SE
+13.04%
current return
Author Info
No bio for this author
Company Info
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany.
Market Cap
$20.2B
Pitch Price
$86.29
Price Target
N/A
Dividend
N/A
EV/EBITDA
-5.94
P/E
-15.64
EV/Sales
2.43
Sector
Biotechnology
Category
special_situation
A Sinister Raise, a Bitter Press Release, and Five Other Weird SEC Filings - BNTX backs its founders
BNTX (overview): Co-founders/execs leaving to start new mRNA co; BNTX contributing mRNA assets for equity stake instead of spinning out to all shareholders. Structure ripe for conflicts—assets could be undervalued to benefit founders at shareholder expense. Stock down ~20% past month on news. Co has ~$20B net cash, promising pipeline readouts ahead, but deal structure raises red flags vs clean spin alternative.
Read full article (2 min)